logo

For the Inventor, By the Inventor

Ann Arbor, MI, United States of America

Ellen Myra Dobrusin

This inventor holds 16 USPTO granted patents, primarily in Kinase Inhibitors. Top assignees: Warner-Lambert Company, Pfizer Corporation, Warner Lambert LLC. Active years: 1995-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ellen Myra Dobrusin. Retrieved from https://idiyas.com/inventor/ellen-myra-dobrusin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 16

% Patents Active = 68.8

Average Co-Inventor Count = 8.0

ph-index = 9

Forward Citations = 316(Granted Patents)


Company Filing History:

goldMedal14 out of 2,538 
 
Warner-Lambert Company
 patents
silverMedal1 out of 4,490 
 
Pfizer Corporation
 patents
bronzeMedal1 out of 22 
 
Warner Lambert LLC
 patents

Years Active: 1995-2010

Loading Chart...
Areas of Expertise:
Tyrosine Kinases
Cell Proliferation
Pyrimidines
Bicyclic Compounds
Checkpoint Kinases
Cyclin-Dependent Kinases
Farnesyl Transferase
Naphthyridinones
Pteridinones
2-Thioindoles
Inhibitors
Protein Kinases
16 patents (USPTO):Explore Patents
1. 7786131 - Pyrimido[5,4-d]pyrimidines derivatives as irreversible inhibitors of tyrosine kinases (2010-08-31),
2. 7501425 - Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation (2009-03-10),
3. 7169778 - Pteridinones as kinase inhibitors (2007-01-30),
4. 7094798 - Inhibitors of checkpoint kinases (Wee1 and Chk1) (2006-08-22),
5. 7053070 - Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors (2006-05-30),
6. 6982260 - Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes (2006-01-03),
7. 6602863 - Irreversible inhibitors of tyrosine kinases (2003-08-05),
8. 6528535 - Bicyclic inhibitors of protein farnesyl transferase (2003-03-04),
9. 6498163 - Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation (2002-12-24),
10. 6344459 - Irreversible inhibitors of tyrosine kinases (2002-02-05),
11. 6300501 - Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase (2001-10-09),
12. 6265422 - Bicyclic inhibitors of protein farnesyl transferase (2001-07-24),
13. 6150359 - Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle (2000-11-21),
14. 6133303 - Bicyclic inhibitors of protein farnesyl transferase (2000-10-17),
15. 5556874 - 2-thioindoles (selenoindoles) and related disulfides (selenides) which (1996-09-17),

Title: The Innovative Journey of Ellen Myra Dobrusin

Introduction: Ellen Myra Dobrusin, a pioneering inventor based in Ann Arbor, MI, has made significant contributions to the field of technology through her inventive spirit and dedication.

Latest Patents: Ellen Myra Dobrusin holds several patents in various technological domains, showcasing her versatility and creativity in innovation.

Career Highlights: With a career spanning over two decades, Ellen Myra Dobrusin has established herself as a prominent figure in the world of inventions. Her work has not only revolutionized existing technologies but has also paved the way for new advancements in the industry.

Collaborations: Throughout her career, Ellen Myra Dobrusin has collaborated with leading tech companies, research institutions, and universities to bring her innovative ideas to life. These collaborations have been instrumental in turning her concepts into tangible inventions that have had a lasting impact on the tech landscape.

Conclusion: Ellen Myra Dobrusin's passion for innovation, coupled with her relentless drive to push the boundaries of technology, has solidified her position as a trailblazing inventor. Her contributions continue to inspire future generations of inventors to think outside the box and pursue their creative visions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…